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Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies. It is phenotypically heterogeneous
with a highly unstable genome and provides few common therapeutic targets. We found that MCL1, Cofilin1 (CFL1) and
SRC mRNA were highly expressed by a wide range of these cancers, suggesting that a strategy of dual MCL-1 and SRC
inhibition might be efficacious for many patients. Immunohistochemistry revealed that MCL-1 protein was present at high
levels in 94.7% of patients in a cohort of PDACs from Australian Pancreatic Genome Initiative (APGI). High MCL1 and
Cofilin1 mRNA expression was also strongly predictive of poor outcome in the TCGA dataset and in the APGI cohort. In
culture, MCL-1 antagonism reduced the level of the cytoskeletal remodeling protein Cofilin1 and phosphorylated SRC on
the active Y416 residue, suggestive of reduced invasive capacity. The MCL-1 antagonist S63845 synergized with the SRC
kinase inhibitor dasatinib to reduce cell viability and invasiveness through 3D-organotypic matrices. In preclinical murine
models, this combination reduced primary tumor growth and liver metastasis of pancreatic cancer xenografts. These data
suggest that MCL-1 antagonism, while reducing cell viability, may have an additional benefit in increasing the antimetastatic
efficacy of dasatinib for the treatment of PDAC.
PDAC is the 8th most common cause of cancer death
worldwide accounting for approximately 430,000 deaths in
2018, being one of the most lethal cancers and exhibiting an
mortality to incidence ratio of 94% [1]. An in-depth
characterization of the pancreatic cancer genomic landscape
[2–4] has revealed great heterogeneity among PDACs
where highly penetrant variants are rare. The translation of
this genomic information into clinical benefit remains a
significant challenge [5] and there is desperate need to
identify new treatments that improve the outcomes of
patients suffering PDAC. In spite of the genomic hetero-
geneity observed in PDAC, the nonreceptor tyrosine kinase
SRC is present at high levels in most PDAC specimens and
pancreatic cancer cell lines. A high level of its activated
form (phosphorylated on Y416) is predictive of poor out-
come among low-grade pancreatic tumors [6, 7]. SRC is a
member of the SRC family kinases (SFK) with pleotropic
roles in the growth, survival, and invasion of pancreatic
cancer [8] and suppression of SRC activity by dasatinib
slows the growth of PDAC models in vitro and in vivo
[9, 10]. Unfortunately the promise of these preclinical
models has not been realized in clinical trials of metastatic
PDAC, where single agent SFK inhibitors alone or in
combination with gemcitabine showed no clinical benefit in
the adjuvant setting [11–13]. Other combinatorial
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approaches show better activity with the triple combination
of dasatinib, erlotinib (an EGFR inhibitor) and gemcitabine
resulting in stable disease in ~70% of patients with tolerable
safety profiles [14]. Thus the activity of agents targeting
SRC may be improved with other targeted therapies that
enhance its activity.
Antagonizing Myeloid cell leukemia 1 (MCL-1) in triple
negative breast cancer (TNBC) can enhance the efficacy of
SFK inhibitors [15]. MCL-1 is a member of the BCL-2
family of proteins that regulate the intrinsic (mitochondrial)
apoptotic cascade, and a mediator of survival in both
healthy and cancerous tissues [16]. MCL-1 protein levels
correlate with outcome, tumor grade and therapeutic resis-
tance in many cancers including those of the hematopoietic
system, breast, lung, and pancreas [17–21]. In preclinical
models of TNBC, we showed that MCL-1 modulated
metastatic progression via two possible mechanisms; firstly
via modulating the output of SFKs and the secondly via
direct regulation of Cofilin. Cofilin is a cytoskeletal remo-
deling protein that is regulated by SRC activity [22, 23] and
essential for actin remodeling during cellular invasion
[24, 25]. As MCL-1 regulated the activity of Cofilin and the
output of the SFKs in breast cancer cells, this led us to
discover that drugs that antagonize MCL-1 can sensitize
TNBC cells to dasatinib and suppress metastatic progres-
sion [15].
As both SRC and MCL-1 are important in the etiology
of multiple cancers [26, 27], we used publicly available
data to identify additional cancer contexts where a com-
bined SRC and MCL-1 inhibitor strategy may be effective,
identifying PDAC as possibly responsive to a dual SRC
and MCL-1 inhibitor therapeutic strategy. We then utilized
patient-derived pancreatic cell lines and orthotopic xeno-
grafts from the APGI to examine whether a dual MCL-1
and SRC inhibitor strategy was an effective antimetastatic
in PDAC.
We first explored the mRNA expression of MCL1, SRC,
and Cofilin1 (CFL1) across cancers in the TCGA and
Australian Pancreatic Genome Initiative (APGI) to identify
contexts where a dual MCL-1, and SRC inhibitor strategy
may be effective. Interrogation of the TCGA datasets using
cBioPortal indicated that MCL1, SRC and CFL1 are
expressed among cholangiocarcinomas and PDACs to a
similar extent to that of invasive breast carcinomas (Fig.
1a). Immunohistochemistry using an antibody to human
MCL-1 on a tissue microarray cohort of 228 pancreatic
cancers (including 188 PDACs, 20 intraductal papillary
mucinous neoplasms with invasion and other mixed sub-
types) from the APGI revealed a large proportion (94.7%)
of PDACs and (90%) of intraductal papillary mucinous
neoplasms with invasion expressed high levels of MCL-1
by IHC consistent with previous reports [28] (Supplemen-
tary Table 1 and Supplementary Fig. 1).
To explore the clinical significance of MCL1, CFL1,
and SRC in PDAC, Kaplan Meier survival analysis was
performed using the mRNA expression quartiles of each
gene from a total of 185 PDAC patients in the TCGA
dataset. This analysis revealed that, although widely
expressed among PDACs, when compared to the lowest
levels of MCL1 in quartile 1, the quartiles with higher
MCL1 mRNA expression were associated with worse
overall survival in PDAC (Fig. 1b). A similar and sig-
nificant pattern was observed using CFL1 mRNA
expression quartiles (Fig. 1c), although the highest com-
pared to the lowest quartiles failed to reach significance.
SRC mRNA expression quartiles were not predictive of
outcome in this cohort (Fig. 1d). There was no association
of MCL1 mRNA expression with either CFL1 or SRC but
we observed a significant positive correlation of SRC
mRNA with CFL1 mRNA (Fig. 1e). We confirmed the
observations made in the TCGA databases using data
obtained from 247 PDAC patients with gene expression
data from the APGI. Clinicopathological information for
this cohort is provided Supplementary Table 2 and in
Bailey et al. [4]. This analysis showed that the highest
levels (top 25% vs. lowest 25%) of both MCL1 and CFL
mRNA correlated with worse overall survival (Fig. 1f, left
panels). The mRNA expression of SRC showed no
prognostic power (Fig. 1f top right panel). When used
together, top quartile levels of both MCL1 and CFL1 were
predictive of worse outcome when compared to lower
quartile levels in the APGI (Fig. 1f bottom right panel).
Western blotting showed that activated SRC (Y416) was a
feature among a panel of patient-derived pancreatic cancer
cell lines (Fig. 1g). The BH3 only pro-apoptotic and
MCL-1 interacting protein BIM was variable across each
line. Furthermore the majority of PDACs were MCL-1
and BCL-XL positive but BCL-2 negative potentially
indicating a preference on either MCL-1 or BCL-XL for
survival.
As the TKCC05 PDAC patient-derived cell line showed
high levels of MCL-1, BIM and total and pSRC levels, this
line was selected to examine the efficacy of a dual MCL-1
and SRC inhibitor strategy. This line can also invade into
3-dimensional collagen I matrices and successfully engraft
as orthotopic xenografts in immune-compromised mice,
spread to the liver and other organs providing a useful
model of pancreatic metastasis [29]. Increasing concentra-
tions of the MCL-1 antagonist S63845 resulted in elevated
levels of MCL-1 similar to what was observed when human
breast cancer cell lines MDA-MB-231 and MDA-MB-468
were treated with S63845 for 48 h (Fig. 2a) [15, 30].
Treatment with 500 nM S63845 produced a significant
suppression of total Cofilin, which was maintained over a
72-h period (Fig. 1b, c) and also resulted in a trend towards
an increased ratio of serine 3 (S3) phosphorylated
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Fig. 1 a Box and whisker graphs of MCL1, SRC, and Cofilin1 (CFL1)
mRNA expression across breast invasive carcinoma (n= 1085), cho-
langiocarcinoma (cholangio-Ca) (n= 36), pancreatic adenocarcinoma
(n= 185) among the TCGA cohort. b Kaplan Meier survival curves of
MCL1 c CFL1, d SRC mRNA expression split by quartiles in the
TCGA PDAC cohorts (n= 185). e mRNA correlation of MCL1
mRNA vs. CFL1 (left panel) and SRC (middle panel) as well as CFL1
vs. SRC (right panel). f Kaplan Meier survival curves of MCL1 (top
left panel), CFL1 (bottom left panel), SRC (top right panel) and
combined MCL1 and CFL1 mRNA expression split by quartiles in the
APGI cohort (n= 247). Log Rank-p-value and hazard ratios indicated.
g Western blots of BCL-2, BCL-XL, BIM, MCL-1, total SRC, Y416
SRC, Y527 SRC, and beta ACTIN among pancreatic cancer cells
derived from the APGI cohort
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(inactivated) Cofilin to total Cofilin at 24 h post treatment
(Fig. 2d). MCL-1 antagonism did not alter the levels of
total SRC but decreased the ratio of Y416 phosphorylated
(activated) SRC to total SRC over the entire 72 h period
suggestive of reduced activity (Fig. 2e). Bliss synergy
analysis showed that the combination of S63845 and
dasatinib (0–25 µM) was synergistic across a wide range of
concentrations at 48 h and 72 h post treatment (Fig. 2f).
We then examined the effects of MCL-1 or SFK antag-
onism alone and in combination in three-dimensional
fibrillar Collagen I matrices in vitro (Fig. 2g [31]). There
were no significant effects of SRC inhibition by dasatinib or
MCL-1 antagonism by A1210477 alone or in combination
on proliferation or apoptosis as measured by Ki67 and
cleaved caspase 3 immunohistochemistry respectively (Fig.
2h, i). However, there was a trend towards enhanced
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apoptosis when S63845 was combined with dasatinib when
administered 5 days post exposure to an air-liquid interface.
This was after when they had begun to invade, mimicking
the clinical presentation of this disease, which often is
associated with local invasion. In contrast dasatinib treat-
ment resulted in a significant and dose dependent decrease
in the ability of TKCC05 cells to invade through the
organotypic matrix. Treatment with A1210477 similarly
reduced their invasive capacity and significantly enhanced
the effects of dasatinib across the dosage range equally
when the drugs were administered just after seeding (Fig. 2h
right panel) and after when they had begun to invade (Fig.
2i, right panel).
We next investigated whether dual inhibition of MCL-1
and SRC would be effective in the treatment of PDACs
in vivo (Fig. 3). TKCC05 patient-derived pancreatic cells
were implanted directly in the pancreas of immune-
compromised NODScidIL2gamma–/– mice and biolumi-
nescent imaging was used confirm successful engraftment
and monitor the growth and spread of TKCC05 patient-
derived pancreatic xenografts over 5 weeks (Fig. 3a). The
rate of expansion of primary pancreatic tumors was not
significantly different between mice treated with vehicle,
S63845, dasatinib or a combination (Fig. 3b) but we
observed a small but significant reduction in the weight of
the primary tumor at 5 weeks post implantation (Fig. 3c).
There were no effects of the single agents on primary tumor
proliferation and apoptosis as measured by Ki67 and
cleaved caspase 3 immunohistochemistry respectively, but a
small and significant decrease in proliferation was observed
in response to combination treatment (Fig. 3d, e). Biolu-
minescent imaging at 5 weeks post surgery suggested that
the combination with S63845 and dasatinib reduced the
spread of the TKCC05 patient-derived pancreatic xeno-
grafts (Fig. 3a). Immunohistochemistry using an antibody to
human MCL-1 in resected PDAC tumors from this model
revealed both nuclear and cytoplasmic staining (Supple-
mentary Fig. 2A). Treatment with S63845 produced a sig-
nificant increase in MCL-1 intensity (Supplementary Fig.
2B) consistent with S63845 extending MCL-1 protein half-
life levels and providing a biomarker of response [30]. Both
the lungs and livers of mice bearing TKCC05 patient-
derived pancreatic xenografts were collected at 5 weeks and
stained with an antibody against human vimentin to high-
light disseminated PDAC cells [32] (Fig. 3f–i). We
observed far fewer metastases in the lungs compared to the
livers at this time point. While no effect of any treatment
was detected in the lungs of these mice (Fig. 3g), the
combination of S63845 and dasatinib produced a significant
reduction in liver metastasis compared to vehicle and single
agent therapy (Fig. 3i).
Here we have shown that MCL-1, Cofilin, and SRC are
widely expressed among PDACs (Fig. 1) with high MCL-1
protein levels detected among 94.7% of all PDACs in the
APGI tissue microarray cohort. Elevated expression of
MCL1 resulted in a two-fold higher risk of death when
compared to patients with the lowest quartile mRNA
expression of MCL1 in the TCGA and APGI cohorts (Fig.
1a, f respectively). Similar observations were true for
Cofilin in both the TCGA (Fig. 1c) and the APGI cohorts
(Fig. 1f), although there was no significant difference
between CFL1 low group and CFL1 high group in the
TCGA cohort (Fig. 1c). Possible reasons for this dis-
crepancy could be the methodology in assessing mRNA
expression (RNAseq in TCGA vs. array based gene
expression in the APGI) as well as a greater number of
patients analyzed in the APGI cohort (247) vs. the TCGA
cohort (185), reaching significance in the APGI cohort. As
Cofilin is tightly linked to SRC activity [22, 23], and we
have shown can be regulated by MCL-1, these data suggest
that up to 75% of patients with PDACs may benefit from a
combinatorial MCL-1 and SFK inhibitor strategy. A similar
benefit could be possible for patients with cancers depen-
dent on MCL-1 and SFK activity via Cofilin e.g. cho-
langiocarcinomas, but this remains to be investigated (Fig.
1a). Furthermore, as 75% of PDACs contain inactivating
mutations in TP53 [33], it is accepted that these tumors are
likely to have an intact apoptotic cascade and therefore
sensitive to antagonism by BH3 mimetics [34]. We have
shown that MCL-1 antagonism can potently sensitize
PDACs to SFK inhibition by dasatinib, and that MCL-1
protein levels as measured by immunohistochemistry could
be used as a biomarker for response. The importance of
SFK in pancreatic cancer is widely recognized [35–37],
hence there has been extensive research into the
Fig. 2 a Western blots of MCL-1 and beta ACTIN from MDA-MB-
231, MDA-MB-468 breast cancer and TKCC05 pancreatic cancer cells
treated with increasing concentrations of S63845. b Western blots and
densitometry quantification of MCL-1 (c), total Cofilin (d, left panel),
ratio of S3 phosphorylated Cofilin/total Cofilin (d, right panel), total
SRC (e, left panel), the ration of Y416 phosphorylated SRC to total
SRC (e, right panel) from TKCC05 pancreatic cancer cells treated with
250 nM S63845 over a 72 h period and normalized to beta ACTIN.
N= 4 independent experiments, error bars, unpaired t-tests between
groups and two-way ANOVA for treatments (vehicle vs. S63845)
indicated. f Bliss synergy contour plot (left panels) and synergy matrix
(right plots) of TKCC05 pancreatic cancer cells treated with increasing
concentrations (0–25 µM) of S63845 and dasatinib at 48 h (upper
panels) and 72 h (lower panels). g Representative immunohistochem-
istry using an antibody to human Vimentin on TKCC05 pancreatic
cancer cells invading into fibrillar Collagen I organotypic matrices and
treated with the indicated concentrations of A1210477 and dasatinib
(h, i). Bar graphs showing the quantification of Ki67 (proliferating
cells, left panels), cleaved caspase 3 (apoptotic cells, middle panels)
and Vimentin (invasion index, right panels) of TKCC05 pancreatic
cancer cells treated with the indicated concentrations of A1210477 and
dasatinib at seeding (upper panels, grid) or 5 days after seeding (lower
panels, invade). Error bars and two-way ANOVA p-value between
treatments indicated
MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma 1825
development of agents that target the SFK in the clinical
setting. Unfortunately the promise of preclinical experi-
ments has been met with disappointment in clinical trials
with single agent dasatinib [11], and Phase II clinical trials
of dasatinib or saracatinib in combination with gemcitabine
failing to show any clinical benefit in patients with
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refractory PDAC [12, 13]. A more recent combination
shows better activity with the triple combination of dasati-
nib, erlotinib (an EGFR inhibitor) and gemcitabine resulting
in stable disease in ~70% of patients with tolerable safety
profiles [14]. Interestingly this combination includes an
agent that antagonizes EGFR, a key growth factor that
controls MCL-1 transcription [38], possibly suggesting that
the success of this trial could be at least, in part, due to the
effects of erlotinib on EGFR driven MCL-1 transcription.
We have previously shown that in the MDA-MB-231
TNBC cell lines in culture, the effects of MCL-1 are largely
limited to its anti-invasive effects possibly via its regulation
of the cytoskeletal remodeling protein Cofilin and/or by the
SFKs [15]. Similarly in PDAC cancer cells, S63845 also
significantly modulated the expression of Cofilin and the
Y416 phosphorylated and activated form of SRC. In addi-
tion, the effects of the S63845 antagonist in combination
with dasatinib were predominantly restricted to outcomes of
cellular invasion (Fig. 2) and metastasis (Fig. 3). These
results suggest that MCL-1 modulation of metastatic pro-
gression via SRC or Cofilin may be present in multiple
cancer contexts. Metastatic progression requires remodeling
of the cytoskeleton, dynamic membrane changes, cellular
invasion and localized tissue destruction [39], and this is
regulated by the SFKs and their targets, including cSRC,
FYN, YES, Paxillin, Cofilin, Cortactin, Rac and Rho
[27, 40]. SRC was not predictive of outcome in the TCGA
or the APGI cohorts but correlated with the expression of
the cytoskeletal remodeling protein Cofilin, consistent with
SRC’s known regulation of this protein [22, 23]. We have
also shown that MCL-1 can modulate Cofilin expression
(Fig. 2). A schematic model for these observations is
provided in Fig. 3h, where MCL-1, a known pro-survival
protein, may directly or indirectly regulate Cofilin expres-
sion via SRC to control invasion. We have already estab-
lished that high levels of MCL-1 place it in close proximity
to Cofilin in breast cancer models [15]. While the full
details underlying this mechanism remain to be discovered,
the data presented here provide a possible explanation as to
why dual antagonism of MCL-1 and SRC is synergistic.
In conclusion we have shown MCL-1 is widely expres-
sed by and can predict outcome in PDAC. Therapeutic
targeting of MCL-1 using BH3 mimetics (e.g., S63845,
A1210477, ADZ5991, MIK665/S64315 etc.) is currently
being investigated in clinical trials for patients with multiple
myeloma, acute myeloid leukemia, and myelodysplastic
syndrome (NCT02992483, NCT02979366 and
NCT03672695) and may provide a way of sensitizing these
tumors to dasatinib and provide a new therapeutic strategy
alone or in combination with standard of care for PDAC.
Materials and methods
All materials and methods are provided in the Supplemen-
tary information
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Fig. 3 a Representative bioluminescent images of mice bearing
TKCC05 pancreatic cancer xenografts at surgery (baseline) or at
5 weeks after surgery (5 weeks) and treated with vehicle (n= 7),
25 mg/kg S63845 (n= 7), 10 mg/kg dasatinib (n= 5, 2 were excluded
from the dasatinib cohort as they reached ethical end point one week
early due to ascites) or combined S63845 and dasatinib (n= 7). b Line
graphs of the average bioluminescence of mice bearing TKCC05
pancreatic cancer xenografts at surgery (baseline) over a 5 week period
treated with vehicle, 25 mg/kg S63845, 10 mg/kg dasatinib or com-
bined S63845 and dasatinib. Dot plots of c tumor weight, d tumor
Ki67 positivity (e) and cleaved caspase 3 positivity in TKCC05 pan-
creatic cancer orthotopic primary tumors. Representative photo-
micrographs taken at ×20 objective of the f lungs and g livers from
mice bearing TKCC05 pancreatic cancer xenografts subjected to
immunohistochemistry using an antibody against vimentin and (h) dot
plots showing the average area of metastasis in the lungs and (i) livers
of mice bearing TKCC05 pancreatic cancer xenografts at 5 weeks post
surgery (each dot is average of 15 images within one mouse).
Unpaired t-tests between groups and one-way ANOVA p-value for
treatments (vehicle vs. S63845) illustrated. j Model schematic of
MCL-1 and SRC regulation of Cofilin. Combined inhibition of MCL-1
by BH3 mimetics such as S63845 and A1210477 can enhance the anti-
invasive effects of dasatinib via a possible direct or indirect regulation
of Cofilin via SRC
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